Anandamide activates human platelets through a pathway independent of the arachidonate cascade  by Maccarrone, Mauro et al.
Anandamide activates human platelets through a pathway independent of
the arachidonate cascade
Mauro Maccarronea, Monica Baria, Adriana Menichellib, Domenico Del Principeb,
Alessandro Finazzi AgroØa;c;*
aDepartment of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via di Tor Vergata 135, I-00133 Rome, Italy
bDepartment of Public Health and Cell Biology, University of Rome Tor Vergata, Via di Tor Vergata 135, I-00133 Rome, Italy
cIRCCS Centro S. Giovanni di Dio, Fatebenefratelli, I-25100 Brescia, Italy
Received 9 February 1999
Abstract Anandamide (arachidonoylethanolamide, AnNH) is
shown to activate human platelets, a process which was not
inhibited by acetylsalicylic acid (aspirin). Unlike AnNH,
hydroperoxides generated thereof by lipoxygenase activity, and
the congener (13-hydroxy)linoleoylethanolamide, were unable to
activate platelets, though they counteracted AnNH-mediated
stimulation. On the other hand, palmitoylethanolamide neither
activated human platelets nor blocked the AnNH effects. AnNH
inactivation by human platelets was afforded by a high-affinity
transporter, which was activated by nitric oxide-donors up to
225% of the control. The internalized AnNH could thus be
hydrolyzed by a fatty acid amide hydrolase (FAAH), character-
ized here for the first time.
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1. Introduction
Anandamide (arachidonoylethanolamide, AnNH) is an en-
dogenous lipid which binds to cannabinoid receptors in the
central nervous system (CB1 receptor) and in peripheral im-
mune cells (CB2 receptor). AnNH is released from depolar-
ized neurons [1] and mimics the pharmacological e¡ects of v9-
tetrahydrocannabinol, the active principle of hashish and mar-
ijuana [2,3]. The manifold pharmacological e¡ects of AnNH
in the central nervous system (reviewed in [4]), as well as its
ability to depress the in£ammatory response of mast cells [5]
and to damp the emerging pain signals at sites of tissue injury
[6], are terminated by a rapid and selective carrier-mediated
uptake into cells, followed by degradation to ethanolamine
and arachidonic acid by the enzyme fatty acid amide hydro-
lase (FAAH).
Human platelets share several receptors and transduction
signaling pathways with neuronal cells [7,8]. It has recently
been shown that AnNH is present in rat blood plasma at
nanomolar concentrations [9]. However, the local concentra-
tion of the lipid can be much higher, due to the local release
of AnNH by macrophages [10] and endothelial cells [11]. Re-
markably, AnNH decreases systemic blood pressure [12] and
has been implicated in the hemorrhagic hypotension, via a
CB1-mediated mechanism [10]. Moreover, AnNH acts as a
vasorelaxant, sharing a common mechanism with the endo-
thelium-derived hyperpolarizing factor [13]. Despite the grow-
ing evidence of the modulation of blood circulation by
AnNH, no information is yet available on the ability of this
lipid in regulating platelet function. This prompted us to in-
vestigate whether human platelets (i) were sensitive to AnNH
stimulation, and (ii) were able to degrade this lipid. The e¡ects
of AnNH metabolites generated by lipoxygenase were also
studied, because the activity of this enzyme has been shown
to play a critical role in the platelet sensitivity to physiological
agonists, such as ADP [14].
2. Materials and methods
2.1. Materials
Chemicals were of the purest analytical grade. Anandamide (arach-
idonoylethanolamide, AnNH), arachidonic acid, palmitic acid, etha-
nolamine, ADP, phenylmethylsulfonyl £uoride (PMSF), sodium nitro-
prusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA). Spermine
NONOate (SPER/NO, (Z)-1-{N-[3-aminopropyl]-N-[4-(3-aminopro-
pylammonio)butyl]-amino}-diazen-1-ium-1,2-diolate) was from Alexis
Corporation (Laºufel¢ngen, Switzerland). Fluo-3/AM was obtained
from Molecular Probes (Eugene, OR, USA). [1-14C]AnNH was syn-
thesized from ethanolamine and [1-14C]arachidonic acid (52 mCi/
mmol, NEN, Boston, MA, USA) as reported [15]. Palmitoylethanol-
amide (PaNH), linoleoylethanolamide (9Z,12Z-octadeca-9,12-dienoyl-
ethanolamide, ODNHEtOH) and the 13-hydroxy derivative 13-
HODNHEtOH were synthesized and characterized (puritys 96% by
gas-liquid chromatography) as reported [16]. 15-Hydro(pero)xyan-
andamide (15-hydro(pero)xyeicosa-5Z,8Z,11Z,13E-tetraenoylethanol-
amide, 15-H(P)AnNH, puritys 96%) and 11-hydro(pero)xyanand-
amide (11-H(P)AnNH, a mixture of 45% 11-H(P)AnNH, 24%
5-H(P)AnNH, 18% 15-H(P)AnNH, 9% 8-/9-H(P)AnNH and 4%
12-H(P)AnNH by reversed phase high performance liquid chroma-
tography) were synthesized as described [17].
2.2. Preparation of human platelets
Blood was drawn from healthy donors who had not taken any
drugs for at least one week before the donation. Blood was collected
into anti-coagulant citrate-dextrose solution (Sigma Chemical Co., St.
Louis, MO, USA), then platelet-rich plasma and washed platelets
were prepared as described previously [18]. Platelets activation was
monitored by the change in light transmission at 650 nm in a model
840 dual-channel Elvi aggregometer (Elvi Logos, Milan, Italy) [19].
Cytosolic calcium concentrations were determined by Fluo-3/AM £u-
orescence, as reported [20]. Dye loading was achieved by incubating
washed platelets (10U106/ml) in 20 WM Fluo-3/AM dissolved in cal-
cium and magnesium-free phosphate-bu¡ered saline (PBS), for 45 min
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at 37‡C. Afterwards, platelets were washed twice in PBS and resus-
pended in Hank’s balanced salt solution (Flow Laboratories Ltd.,
Herts, UK). Fluorescence was measured in a FACSCalibur cyto-
£uorimeter (Becton-Dickinson, CA, USA). Platelet morphology was
analyzed by standard cyto£uorimetric procedures.
2.3. Characterization of fatty acid amide hydrolase (FAAH)
Washed platelets (4U109) were collected in phosphate-bu¡ered sal-
ine and centrifuged at 1000Ug for 10 min. The dry pellet was resus-
pended in 1 ml ice-cold 50 mM Tris-HCl, pH 7.4, containing 1 mM
EDTA (bu¡er A) and sonicated on ice three times for 10 s, with 10 s
intervals, using a Vibracell soni¢er (Sonics and Materials Inc., Dan-
bury, CT, USA) with a microtip at maximum power. Membranes
from platelet homogenates were then prepared as described [21,22]
and the ¢nal pellet, containing most FAAH activity [23,24], was re-
suspended in 100 Wl ice-cold bu¡er A at a protein concentration of
1 mg/ml and stored at 380‡C until use.
FAAH (E.C. 3.5.1.4, arachidonoylethanolamide amidohydrolase)
activity was assayed by reversed phase high performance liquid chro-
matography (RP-HPLC), as described [15]. Kinetic studies were per-
formed using di¡erent concentrations of [1-14C]AnNH (in the range
0^30 WM). Kinetic parameters were calculated by ¢tting the experi-
mental points to a Lineweaver-Burk plot with a linear regression
programme (Kaleidagraph 3.0). Straight lines with r values s 0.95
were obtained. The e¡ect of various compounds on the hydrolase
activity of FAAH was determined by adding directly each substance
to the assay bu¡er, at the indicated concentrations.
Immunochemical analysis of human platelet FAAH was performed
by SDS-polyacrylamide gel electrophoresis (12%), under reducing
conditions, in a Mini Protean II apparatus (Bio-Rad, Richmond,
CA, USA) with 0.75 mm spacer arms [25]. Rainbow molecular weight
markers (Amersham, Buckinghamshire, UK) were phosphorylase b
(97.4 kDa), bovine serum albumin (66.0 kDa) and ovalbumin (46.0
kDa). Platelet homogenates (20 Wg/lane), prepared as described above
for FAAH assay, were subjected to SDS-polyacrylamide gel electro-
phoresis, then slab gels were electroblotted onto 0.45 Wm nitrocellu-
lose ¢lters (Bio-Rad), using a Mini Trans Blot apparatus (Bio-Rad) as
reported [25]. Immunodetection of FAAH on nitrocellulose ¢lters was
performed with speci¢c anti-FAAH polyclonal antibodies (diluted
1:200), elicited in rabbits against the conserved FAAH sequence
VGYYETDNYTMPSPAMR [26], conjugated to ovalbumin. This
peptide antigen and the anti-FAAH polyclonal antibodies were pre-
pared by Primm S.r.l. (Milan, Italy). Goat anti-rabbit alkaline phos-
phatase conjugate (GAR-AP, Bio-Rad), diluted 1:2000, was used as
second antibody and immunoreactive bands were stained with the
alkaline phosphatase staining solution according to the manufactur-
er’s instructions (Bio-Rad).
2.4. Determination of anandamide uptake
The uptake of [1-14C]AnNH (52 mCi/mmol) by intact platelets was
studied essentially as described [23], using 2U108 platelets in 2 ml
phosphate-bu¡ered saline (PBS) in each test. Suspensions of human
platelets were incubated for 20 min at 37‡C with [1-14C]AnNH in the
0^1000 nM range, then they were washed three times in PBS contain-
ing 1% bovine serum albumin and were ¢nally resuspended in 200 Wl
PBS. Membrane lipids were then extracted [27], resuspended in 0.5 ml
methanol, mixed with 3.5 ml Sigma-Fluor liquid scintillation cocktail
for non-aqueous samples (Sigma), and radioactivity was measured in
a LKB1214 Rackbeta scintillation counter (Sweden). Control experi-
ments were carried out at 4‡C, in order to check whether AnNH
import into cells took place by facilitated transport or by simple
di¡usion [23]. Q10 value was calculated as the ratio of AnNH uptake
at 30‡C and 20‡C [28]. Apparent Km and Vmax values of the uptake
kinetics were calculated by Lineweaver-Burk analysis (in this case, the
uptake at 4‡C was subtracted from that at 37‡C). AnNH uptake was
expressed as pmol AnNH taken up per min per mg protein. The e¡ect
of di¡erent compounds on AnNH uptake was determined by adding
each substance directly to the incubation medium, at the indicated
concentrations.
2.5. Data analysis
Data reported in this paper are the mean ( þ S.D.) of at least three
independent determinations, each in duplicate. Statistical analysis was
performed by the Student’s t-test, elaborating experimental data by
means of the InStat programme (GraphPad Software).
3. Results
Washed platelets were activated by 1.3 mM AnNH, a proc-
ess which reached a maximum 3 min after addition of the lipid
(Fig. 1A). Activation of platelets by AnNH was superimpos-
able to that by arachidonate at the same concentration (not
shown), though it was not a¡ected by co-incubation with
either 100 WM PMSF or 100 WM ASA (aspirin) (Fig. 1A).
Unlike AnNH, its hydro(pero)xy derivatives 11-H(P)AnNH
and 15-H(P)AnNH, and the congeners ODNHEtOH and
13-HODNHEtOH, did not activate human platelets, but
they abolished the e¡ect of AnNH when added together at
the same concentration (Fig. 1A). Platelet activation by
AnNH was dose-dependent, reaching a maximum at 1.3
mM (Fig. 1B). Instead, palmitoylethanolamide (PaNH) was
unable to activate platelets in the same concentration range
(Fig. 1B) and did not interfere with the e¡ect of AnNH (data
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Fig. 1. A: Washed platelets were treated with 1.3 mM AnNH, alone
(circles) or in the presence of 100 WM PMSF (triangles), 100 WM
ASA (squares), 1.3 mM 11-H(P)AnNH (diamonds) or 1.3 mM
ODNHEtOH (empty circles). B: Dose-dependent activation of
platelets by AnNH (circles) or PaNH (triangles).
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not shown). Platelet activation by millimolar concentrations
of AnNH was not observed in platelet-rich plasma, while it
a¡orded the ‘ADP priming’, i.e. it was able to make irrever-
sible platelet activation induced by 0.2 WM ADP (data not
shown).
The e¡ects of AnNH and arachidonic acid on the overall
morphology of washed platelets (i.e. cell size and complexity)
under the same conditions were superimposable (Fig. 2). Like
arachidonic acid, the e¡ect of AnNH on platelets could be
attributed to a remarkable increase in cytosolic calcium con-
centration, which again was not a¡ected by either 100 WM
PMSF or 100 WM ASA (Fig. 3A). Unlike AnNH, its deriva-
tives 11-H(P)AnNH and 15-H(P)AnNH, and the congeners
ODNHEtOH and 13-HODNHEtOH, caused only a modest
increase of cytosolic calcium concentration (Fig. 3B), which
was even less upon treatment of platelets with PaNH (Fig.
3C).
Intact platelets were able to accumulate [14C]AnNH, a
process which was temperature- (Q10 = 1.5), time- (t1=2 =
5 min) and concentration-dependent (Fig. 4A and data not
shown). [14C]AnNH uptake was saturable (Km = 0.20 þ 0.02
WM, Vmax = 22 þ 2 pmol min31 mg protein31) at 37‡C. The
uptake was enhanced when the incubations were carried out
in the presence of NO-donors such as SNP (Fig. 4B), SNAP
or SPER-NO (not shown). These donors were used at milli-
molar concentrations which release physiological nanomolar
concentrations of NO in solution [29,30]. Enhancement of
[14C]AnNH uptake by SNP was prevented by the presence
of hemoglobin (Fig. 4B), a typical NO scavenger [31]. Con-
versely, the alkylating agents PMSF, iodoacetic acid or N-
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Fig. 2. Washed platelets, resting (A) or stimulated for 1 min with 1.3 mM AnNH (B) or arachidonic acid (C), were analyzed by cyto£uorimetry
for cell size (forward scatter-height, FSC-H) and complexity (side (90‡) scatter-height, SSC-H).
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ethylmaleimide, each used at 100 WM ¢nal concentration, re-
duced AnNH uptake by platelets to approximately 40% of the
untreated control (data not shown). Finally, 10 WM arachi-
donic acid, 11-H(P)AnNH, 15-H(P)AnNH, ODNHEtOH or
13-HODNHEtOH did not a¡ect the [14C]AnNH uptake by
intact platelets (not shown).
Platelets also showed a remarkable FAAH activity, which
hydrolyzed AnNH in a Michaelis-Menten way (Fig. 5A).
Lineweaver-Burk plot of FAAH-catalyzed hydrolysis of
AnNH allowed to calculate an apparent Km = 10 þ 1 WM
and Vmax = 270 þ 30 pmol min31 mg protein31. Western blot-
ting of platelet homogenates (20 Wg/lane) showed that anti-
FAAH polyclonal antibodies speci¢cally recognized a single
immunoreactive band, corresponding to a molecular weight of
approximately 67 kDa (Fig. 5B). The alkylating agents
PMSF, iodoacetic acid or N-ethylmaleimide, each used at
100 WM ¢nal concentration, almost completely inhibited
FAAH (data not shown). The same inhibition and electro-
phoretic patterns have been recently shown in human brain
FAAH [32].
4. Discussion
Platelets are small disc-shaped cell fragments which under-
go a rapid transformation upon vascular damage. They soon
become more spherical and extrude pseudopodia, eventually
forming a plug which is responsible for primary hemostasis.
Activation of platelets is also implicated in the pathogenesis of
unstable angina, myocardial infarction and stroke [33]. Plate-
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Fig. 3. Intracellular calcium concentration was measured in washed
platelets, upon treatment with A: 1.3 mM AnNH; B: 1.3 mM
11-H(P)AnNH, 15-H(P)AnNH, ODNHEtOH or 13-HODNHEtOH;
C: 1.3 mM PaNH. Treatment of platelets with 1.3 mM AnNH in
combination with 100 WM PMSF or ASA yielded the same results
as treatment with 1.3 mM AnNH alone (panel A). Arrows indicate
the addition of each compound to the platelet suspension.
Fig. 4. A: Dependence of [14C]AnNH uptake by human platelets
(20 min) on AnNH concentration, at 37‡C (circles) or 4‡C (trian-
gles). B: E¡ect of nitric oxide-donor SNP, alone (empty bars) or in
combination with 20 WM hemoglobin (hatched bars) on the uptake
of 200 nM [14C]AnNH. Uptake was expressed as percentage of the
untreated control (100% = 10 þ 1 pmol min31 mg protein31).
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lets can be also stimulated ‘in vitro’ by physiological agonists
such as arachidonic acid and ADP, which induce a shape
change of platelets, from smooth discs to spiculated spheres,
with emission of pseudopodia which may lead to their aggre-
gation [7,8,14]. A common metabolic response of platelets to
these agonists is the increase in cytosolic calcium [7,8,14].
Hemorrhagic shock [10], and more in general peripheral
tissue injury [12], can be induced by anandamide, which is
present in blood plasma at nanomolar concentrations [9] but
if released locally by macrophages and endothelial cells it can
reach even higher concentrations [10,11]. We have found that
AnNH much alike arachidonic acid can activate human plate-
lets, with a similar time-course and at the same concentration
(Fig. 1A). Furthermore, AnNH induces the same morpholog-
ical changes (Fig. 2B and C) and increases intracellular cal-
cium concentration as arachidonic acid (Fig. 3A and data not
shown). However, AnNH-induced activation of platelets was
insensitive to ASA (Figs. 1A and 3A), which abolishes the
e¡ect of arachidonic acid through the inhibition of cyclooxy-
genase [34], thus preventing the formation of the potent plate-
let agonist thromboxane A2. Moreover, PMSF, which inhibits
the FAAH-catalyzed release of arachidonate from AnNH,
did not a¡ect platelet activation by AnNH (Fig. 1A), support-
ing the hypothesis that AnNH acts through a pathway inde-
pendent of arachidonate metabolism.
The interaction of human platelets with AnNH derivatives
was further characterized, because lipoxygenase activity of
platelets, mainly due to a 12-lipoxygenase isozyme, has been
shown to play a critical role in modulating platelet response to
physiological stimuli [14]. AnNH hydro(pero)xides, which are
produced by lipoxygenases [35], were unable to activate hu-
man platelets, but prevented the activation by AnNH (Fig.
1A). A similar e¡ect was observed with linoleoylethanol-
amide, normally present in neurons [1], and with the 13-hydro-
peroxide generated thereof by lipoxygenase (Fig. 1A). Instead,
palmitoylethanolamide, whose activity in mast cells [5] and
skin [6] is antagonized by AnNH, did not show any e¡ect
on platelets (Fig. 1B) nor antagonized AnNH (not shown).
This evidence and the observation that AnNH was active only
at millimolar concentration (Fig. 1B), seem to rule out a CB1
or CB2 receptor-mediated platelet activation. The nature of
AnNH target on platelet surface remains to be elucidated, but
it is well known that the platelet stimulus-response coupling is
often very complex. For instance, ADP has been known to
activate platelets since 1961, but only recently it has been
shown that four di¡erent receptors, each coupled to a di¡er-
ent signaling pathway, are required for its action [7,8]. Even
though AnNH did not activate platelets under more physio-
logical conditions, i.e. in platelet-rich plasma, the observed
synergistic e¡ect of this lipid on ADP-induced platelet activa-
tion may suggest a physiological role for this compound.
That AnNH might be an important signal molecule for
human platelets is also suggested indirectly by the observation
that these cells possess the machinery to degrade this lipid.
Indeed, human platelets showed a remarkable FAAH activity,
which was attributable to a single protein of 67 kDa (Fig. 5).
This molecular weight was in good agreement with the full-
length human liver FAAH cDNA [26]. The catalytic and mo-
lecular properties of platelet FAAH are close to those ob-
served in human brain and human neuronal (CHP100) and
immune (U937) cell lines [32]. In every case, FAAH activity
was inhibited by alkylating agents PMSF, iodoacetic acid and
N-ethylmaleimide, suggesting that a cysteine residue might be
critical for enzyme activity [36].
In order to be hydrolyzed by FAAH, AnNH has to be
imported into the cell. Recent experiments performed on rat
neuronal cells [28,37], rat basophilic leukemia (RBL-2H3)
cells and mouse J774 macrophages [23] clearly showed the
presence of a high-a⁄nity AnNH transporter in the cell outer
membranes. A similar methodology was used here to charac-
terize the AnNH uptake by human platelets. These cells rap-
idly took up AnNH (t1=2 = 5 min), in a temperature-dependent
(Q10 = 1.5) and saturable way (Fig. 4A and data not shown).
The a⁄nity of the transporter for AnNH in human platelets
was comparable to that of rat astrocytes (Km = 0.32 WM) [37].
Furthermore, the uptake of AnNH by human platelets was
una¡ected by arachidonic acid, AnNH derivatives and con-
geners, leukotriene B4 or prostaglandin E2 (not shown), sug-
gesting that AnNH accumulation is selective and mediated by
a transporter di¡erent from the long chain fatty acid transport
protein [38] or the prostaglandin transporter [39]. This ¢nding
is in keeping with recent data on the AnNH carrier of rat
neurons and astrocytes [37] and human cells in culture [32].
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Fig. 5. A: FAAH activity was assayed by incubating 20 Wg platelet
homogenate with di¡erent amounts of anandamide, for 15 min at
37‡C. B: Western blot analysis of platelet homogenates (20 Wg/lane),
separated by 12% SDS-PAGE and reacted with speci¢c anti-FAAH
polyclonal antibodies.
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As reported for other human cells, AnNH uptake by platelets
was increased by NO-donors SNP (Fig. 4B), SNAP or SPER/
NO (not shown). NO is a vasodilator with anti-aggregating
properties, which is released by human endothelial cells, gran-
ulocytes and monocytes upon stimulation of opiate and can-
nabinoid receptors [40]. The NO-mediated enhancement of
AnNH uptake by platelets is coherent with the anti-aggregat-
ing properties of this molecule, because a faster AnNH re-
moval from the extracellular space, followed by hydrolysis
inside platelets, should decrease the concentration of AnNH,
thus preventing platelet aggregation. On the other hand, al-
kylating agents PMSF, iodoacetic acid and N-ethylmaleimide
(not shown) reduced AnNH uptake down to approximately
50% of the control, suggesting the presence of a cysteine res-
idue in the active site of the transporter. The alkylation of this
residue might reduce the velocity of AnNH import, while a
nitrosylation seems to have the opposite e¡ect.
In conclusion, the results reported here show that human
platelets can be activated by AnNH, in a way independent of
the arachidonate cascade. They also bring information on
human platelet FAAH and AnNH transporter. In addition,
they suggest that the hydro(pero)xides of arachidonate and
linoleate ethanolamides generated by lipoxygenase activity
might be important natural antagonists of human platelet
aggregation.
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